Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose-escalation and Dose-expansion Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer

NCT07587827 is registered in ClinicalTrials.gov with Centre Georges Francois Leclerc as lead sponsor.

NCT NCT07587827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07587827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose-escalation and Dose-expansion Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer
Lead sponsor
Centre Georges Francois Leclerc
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
May 1, 2031
Enrollment
77 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced colorectal cancer, locally advanced pancreatic cancer, metastatic colorectal cancer (crc), metastatic pancreatic cancer